News Releases

 May 29, 2026
Quest PharmaTech Provides Corporate Update including Voluntary

Adoption of CSA Blanket Order 51-93 to File Financial Statements and

MD&A on Semi-Annual Basis 

Aug 27, 2025
Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech

Jun13, 2025
Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech

 Jun 2, 2025
Quest PharmaTech Provides Corporate Update

 Oct 11, 2024
Quest PharmaTech Announces Results from AGM

 May 30, 2024
Quest PharmaTech Announces Filing of 2024 Year End Financial Statements and Restated Fiscal 2023 Financial Statements, and Appointment of New Director 

 January 30, 2024
Quest Receives Cash Dividend Payment from OncoQuest 

 January 23, 2024
Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits